PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 7, 2026Obesity0 citations

Glucagon‐Like Peptide‐1 Receptor Agonists: Considerations for Treating Preconception Obesity

View Full Paper
LBLauren T. BerubeMWMichael A. WeintraubHBHedda L Boege

Key Points

  • To explore the effectiveness of glucagon-like peptide-1 receptor agonists in treating obesity before conception.
  • Review of clinical guidelines
  • Discussion of obesity management approaches
  • Analysis of hormonal impacts on preconception health
  • GLP-1 receptor agonists may aid in weight management for preconception obesity
  • Guidelines recommend integrating these medications into treatment plans for at-risk women

Abstract

M.A.W. has received speaker honoraria from the American Board of Obesity Medicine, the Endocrine Society, Weill Cornell, and St. John's hospital and served as a co-chair of the Endocrine Society Clinical Practice Guideline. C.R.S. has received consulting fees from the Agency for Toxic Substance and Disease Registry (ATSDR), Office of Science. A.L.D. has served on the Advisory Committee for the 2025 U.S. Dietary Guidelines and the Editorial Board for the Obesity journal. The other authors declare no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Berube et al. (2026) studied this question.

synapsesocial.com/papers/69fbefa3164b5133a91a3a20https://doi.org/10.1002/oby.70210
Ask AI
Helpful
Bookmark
Share
View Full Paper